ALAlphabet Inc.

Institutional investor · Portfolio as of Q1 2024

Top Holdings43 positions

Checking export access…
Activity:

GITLAB INCCL A

9.8M$569.1M22.6%$54.98+6.08%
8 qtrssince 2022-Q2
Increased
100

CROWDSTRIKE HLDGS INC

855,789$274.4M10.9%$30.67+161.35%
6 qtrssince 2022-Q4
Decreased
0

DEXCOM INC

1.8M$248.4M9.9%$115.76+19.82%
19 qtrssince 2019-Q3
Decreased
0
ARMARM
ADR

ARM HOLDINGS PLC

2M$245.1M9.7%$53.52+133.54%
3 qtrssince 2023-Q3
Unchanged
0

FRESHWORKS INCCL A

12.3M$224.7M8.9%$20.84-12.63%
10 qtrssince 2021-Q4
Increased
97

REVOLUTION MEDICINES INC

5.3M$170.9M6.8%$28.68+12.38%
2 qtrssince 2023-Q4
Unchanged
0
VERVVERVDelisted

VERVE THERAPEUTICS INC

12.3M$164M6.5%——
12 qtrssince 2021-Q2
Unchanged
0

UIPATH INC CLASS A

7M$159.5M6.3%$67.93-66.63%
12 qtrssince 2021-Q2
Unchanged
0

PRIME MEDICINE INC

15.1M$105.4M4.2%$16.12-56.58%
6 qtrssince 2022-Q4
Increased
69

SNOWFLAKE INC

535,604$86.6M3.4%$229.13-29.47%
9 qtrssince 2022-Q1
Unchanged
0

PLANET LABS PBC

31.9M$81.5M3.2%$6.15-58.54%
10 qtrssince 2021-Q4
Unchanged
0

SANA BIOTECHNOLOGY INC

2.8M$28.1M1.1%$33.47-70.12%
13 qtrssince 2021-Q1
Unchanged
0

INVIVYD INC

4.5M$20.1M0.8%$42.24-97.40%
11 qtrssince 2021-Q3
Decreased
0

LYELL IMMUNOPHARMA INC

5.9M$13.1M0.5%$324.80-86.27%
12 qtrssince 2021-Q2
Unchanged
0

RELAY THERAPEUTICS INC

1.6M$13M0.5%$41.71-80.10%
15 qtrssince 2020-Q3
Unchanged
0

BEAM THERAPEUTICS INC

321,604$10.6M0.4%$18.00+83.56%
17 qtrssince 2020-Q1
Unchanged
0

VERA THERAPEUTICS INC

241,264$10.4M0.4%——
12 qtrssince 2021-Q2
Decreased
0

MONTE ROSA THERAPEUTICS INC

1.5M$10.3M0.4%$22.70-68.94%
12 qtrssince 2021-Q2
Unchanged
0
DMDMDelisted

Desktop Metal Inc

11M$9.7M0.4%——
14 qtrssince 2020-Q4
Unchanged
0

TSCAN THERAPEUTICS INC

1.1M$8.6M0.3%$8.34-4.80%
11 qtrssince 2021-Q3
Unchanged
0
$2.5B
AUM
43
Positions
Q1 2024
Filing
HI score · 2.5/5
Quarterly 13F Value Change
-12%Q4'22$1.7B+5%Q1'23$1.8B+3%Q2'23$1.9B-16%Q3'23$1.6B+39%Q4'23$2.2B+17%Q1'24$2.5B
Activity profile
$ moved · Q1'24
New1%Increased65%Decreased34%Exited1%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 1.2 years
<1Q2%1-4Q7%1-2Y91%2Y+0%

Alphabet Inc. manages $2.5B across 43 positions as of Q1 2024. Top holdings: GTLB (22.6%), CRWD (10.9%), DXCM (9.9%). Fund DNA: Concentrated Value. HoldingsIntel Score: 2.5/5.0.

Q1 2024 Summary

Added GUTS; exited NMRA and SNCE; increased 3, led by GTLB (+7.1M shares); trimmed 5, led by DXCM (−1.9M shares). Top move: GTLB (INCREASED, conviction 100). Portfolio: $2.5B across 43 positions.

Top holdings by portfolio weight

Total AUM$3B
GTLB22.64%
CRWD10.91%
DXCM9.88%
ARM9.75%
FRSH8.94%
RVMD6.80%
VERV6.52%
PATH6.34%
PRME4.19%
SNOW3.44%
Other3.24%

Portfolio allocation by GICS sector

Sectors4
Technology62.03%
Healthcare27.62%
Unknown7.11%
Industrials3.24%

Behavioral investing profile

Checking access…
Concentrated Value- primarily Technology, Healthcare
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Solid(2.5 / 5.0)
Holdings P&L45
Conviction36
Concentration100
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

No active accumulation streaks detected for this filer.

Streaks require 2+ consecutive quarters of increased positions in the most recent period.

Famous Investors' Portfolios

What the most-followed managers hold, and what they bought and sold each quarter.

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used